HROW News and Press, Harrow Health Inc. From 11/10/25

2025-11-10 16:11:49 ET More on Harrow Health Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other Harrow, Inc. (HROW) Analyst/Investor Day Transcript Harrow Health Q...

Third-Quarter 2025 and Recent Selected Highlights: Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year period GAAP net income of $1.0 million Adjusted EBITDA of $22.7 million Cash and cash equivalents of $74.3 million as of September 3...

VEON Ltd. (VEON) is expected to report $1.21 for Q3 2025 eToro Group Ltd. (ETOR) is expected to report $0.52 for Q3 2025 KE Holdings Inc American Depositary Shares (each representing three Class A) (BEKE) is expected to report $0.09 for Q3 2025 CoreWeave Inc. (CRWV) is expected to rep...

2025-11-07 17:35:16 ET More on Harrow Health Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other Harrow, Inc. (HROW) Analyst/Investor Day Transcript Harrow to buy M...

2025-11-05 12:31:13 ET With its Q3 earnings due to be reported in five days' time, on tenth November, I thought this would be a good time to initiate my first coverage of Harrow Inc, an ophthalmology company with seemingly strong growth prospects that has been in business since 2008. ...

NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, after ...

2025-10-26 09:45:35 ET On Wednesday, Avadel Pharmaceuticals ( AVDL ) accepted a buyout off from Alkermes plc ( ALKS ) after settling litigation with Jazz Pharmaceuticals ( JAZZ ) . It should be noted this just the latest of several notable acquisi...

2025-10-15 21:03:41 ET Article Thesis I wrote about Harrow, Inc. ( HROW ), a small biotech company focused on acquiring and commercializing ophthalmic pharmaceutical products in the U.S., at the beginning of September. With a price around $37 and a Fair Value estimate of...

2025-10-06 07:44:09 ET More on Harrow Health Harrow, Inc. (HROW) Analyst/Investor Day Transcript Harrow: Buy A Blend Of Value And Growth Harrow: A Classical GARP Stock Harrow to buy Melt Pharmaceuticals Harrow launches $250M debt offering Re...

Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today ...